Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech, with six clinical and over 50 small molecule discovery/pre-clinical programs. Through risk/reward-sharing alliances with GlaxoSmithKline, Lilly, Janssen Pharmaceutica, Merck & Co., Roche and Servier, Galapagos is eligible to receive up to €3.3 billion in downstream milestones, plus royalties. The Galapagos Group has over 800 employees and operates facilities in seven countries, with global headquarters in Mechelen, Belgium.
Type
Public
HQ
Mechelen, BE
Founded
1999
Employees
462 (est)
Galapagos was founded in 1999 and is headquartered in Mechelen, BE

Key People at Galapagos

Onno van de Stolpe

Onno van de Stolpe

CEO
Werner Cautreels

Werner Cautreels

Director

Galapagos Locations

Mechelen, BE

Galapagos Metrics

Galapagos Summary

Market capitalization

€2570 B

Closing share price

€55.8
Galapagos's latest market capitalization is €2570 B.

Galapagos Market Value History

Galapagos News

Galapagos Company Life

You may also be interested in